Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results

Motzer, R.; Ravaud, A.; Patard, J.; Pandha, H.; George, D.; Patel, Anup; Chang, Yen‐Hwa; Escudier, B.; Donskov, F.; Magheli, A.; Cartenì, G.; Laguerre, B.; Tomczak, P.; Breza, J.; Gerletti, P.; Lechuga, M.; Lin, Xun; Casey, M.; Serfass, L.; Pantuck, A.; Staehler, M.

doi:10.1016/j.eururo.2017.09.008

Public

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results

Published in European urology • Sep 28, 2017

Authors:

R. Motzer

A. Ravaud

J. Patard

Abstract

Background Adjuvant sunitinib significantly improved disease-free survival (DFS) versus placebo in patients with locoregional renal cell carcinoma (RCC) at high risk of recurrence after nephrectomy (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.59–0.98; p = 0.03). Objective To report the re...

View

Open Access

Subject

Medicine

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!